Inclusion Criteria:  Relapsing Multiple Sclerosis (RMS) diagnosis eligible for ofatumumab treatment willing and eligible to receive SARS-CoV-2 mRNA vaccine  Exclusion Criteria:  known prior or current COVID-19 infection previous treatment with BTK inhibitor or anti-CD20 therapy other than ofatumumab  Other protocol-defined inclusion/exclusion criteria may apply